Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Circulation: Cardiovascular Interventions

Volumn 8, Issue 4, 2015, Pages

  Kereiakes, Dean J ^a   Meredith, Ian T ^b   Windecker, Stephan ^c   Jobe, R Lee ^d   Mehta, Shamir R ^e   Sarembock, Ian J ^a   Feldman, Robert L ^f   Stein, Bernardo ^g   Dubois, Christophe ^h   Grady, Timothy ⁱ   Saito, Shigeru ^j   Kimura, Takeshi ^k   Christen, Thomas ^l   Allocco, Dominic J ^l   Dawkins, Keith D ^l  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b MONASH MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF BERN   (Switzerland)

^d WAKEMED HEALTH AND HOSPITALS   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f Munroe Regional Med Center   (United States)

^g Morton Plant Mease Health System   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ Aspirus Heart and Vascular Institute   (United States)

^j SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^k KYOTO UNIVERSITY HOSPITAL   (Japan)

^l BOSTON SCIENTIFIC CORPORATION   (United States)

more..

Author keywords

drug eluting stent; percutaneous coronary intervention

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE APPROVAL; DEVICE COMPARISON; DEVICE FAILURE; DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STABLE CORONARY ARTERY DISEASE; STENT THROMBOSIS; ACUTE CORONARY SYNDROME; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; BLOOD VESSEL TRANSPLANTATION; CHEMISTRY; CLINICAL TRIAL; DRUG ELUTING STENT; MIDDLE AGED; TREATMENT OUTCOME; UTILIZATION;

BIOMATERIAL; DILACTIDE; DIOXANE DERIVATIVE; EVEROLIMUS; PLATINUM DERIVATIVE; POLYMER;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ARTERY DISEASE; DIOXANES; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATINUM COMPOUNDS; POLYMERS; TREATMENT OUTCOME;

EID: 84937424511     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002372     Document Type: Article

References (27)

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44-e122. Doi: 10. 1016/j. jacc. 2011. 08. 007.
2. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. Doi: 10. 1161/01. CIR. 0000116202. 41966. D4.
3. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents vs. Bare metal stents vs. Durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35:1147-1158. Doi: 10. 1093/eurheartj/eht570.
4. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. Durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-994. Doi: 10. 4244/EIJV7I8A155.
5. Palmaz JC, Bailey S, Marton D, Sprague E. Influence of stent design and material composition on procedure outcome. J Vasc Surg. 2002;36:1031-1039.
6. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Lee PV, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New Engl J Med. 2014;371:2155-2166. Doi: 10. 1056/NEJMoa1409312.
7. Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrié D, Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimuseluting coronary stent. J Am Coll Cardiol. 2012;59:1362-1370. Doi: 10. 1016/j. jacc. 2011. 12. 016.
8. Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbak H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013;9:308-315. Doi: 10. 4244/EIJV9I3A52.
9. Menown IB, Noad R, Garcia EJ, Meredith I. The platinum chromium element stent platform: from alloy, to design, to clinical practice. Adv Ther. 2010;27:129-141. Doi: 10. 1007/s12325-010-0022-9.
10. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-1708. Doi: 10. 1016/j. jacc. 2011. 02. 016.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. Doi: 10. 1161/ CIRCULATIONAHA. 106. 685313.
12. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-2441. Doi: 10. 1161/CIRCULATIONAHA. 107. 693739.
13. Vorpahl M, Finn AV, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention. 2009;5(suppl F):F28-F35. Doi: 10. 4244/EIJV5IFA5.
14. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. Doi: 10. 1016/j. jacc. 2006. 03. 042.
15. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011;4:38-46. Doi: 10. 1161/CIRCINTERVENTIONS. 110. 957654.
16. Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57:567-584.
17. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330-342. Doi:101161/CIRCINTERVENTIONS. 113. 000990.
18. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777-789. Doi: 10. 1016/j. jcin. 2013. 04. 011.
19. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.
20. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-1402. Doi: 10. 1016/S0140-6736(12)60324-9.
21. Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014;7:55-63. Doi: 10. 1016/j. jcin. 2013. 07. 012.
22. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-1409. Doi: 10. 1161/ CIRCULATIONAHA. 110. 003210.
23. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; NEXT Investigators. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181-190. Doi: 10. 1016/j. jacc. 2013. 04. 045.
24. Eppihimer M. Impact of polymer type and location on stent thrombogenicity and endothelial cell coverage. EuroIntervention. 2013; EuroPCR Abstracts 2013: Abstract 341.
25. Eppihimer MJ, Sushkova N, Grimsby JL, Efimova N, Kai W, Larson S, Forsyth B, Huibregtse BA, Dawkins KD, Wilson GJ, Granada JF. Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces. Circ Cardiovasc Interv. 2013;6:370-377. Doi: 10. 1161/CIRCINTERVENTIONS. 113. 000120.
26. Wilson GJ, Huibregtse BA, Pennington DE, Dawkins KD. Comparison of the SYNERGY with the PROMUS (XIENCE V) and bare metal and polymer-only Element control stents in porcine coronary arteries. EuroIntervention. 2012;8:250-257. Doi: 10. 4244/EIJV8I2A39.
27. Yeh RW, Czarny MJ, Normand SL, Kereiakes DJ, Holmes DR Jr, Brindis RG, Weaver WD, Rumsfeld JS, Roe MT, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015;8:96-102. Doi: 10. 1161/CIRCOUTCOMES. 114. 001239.